After many years of limited therapeutic opportunities, the treatment of type 2 diabetes has become more target and pathophysiologically driven. A typical example is represented by the development of the dipeptidyl peptidase-4 (DPP-4) inhibitors, allowing for more physiological regulation of the endocrine pancreas and leading to a previously unmet risk-to-benefit balance. Vildagliptin, one of the earliest DPP-4 inhibitors, has been tested across the entire spectrum of type 2 diabetes and has been in clinical use for 20 years. This publication critically reviews the main steps in the clinical development of this agent.
Type 2 diabetes, DPP-4 inhibitors, vildagliptin
Stefano Del Prato has received research support from AstraZeneca,
MSD, Novartis and Boehringer Ingelheim, and consultancy fees from AstraZeneca,
Boehringer Ingelheim, Eli Lilly, GSK, MSD, Novartis, Novo Nordisk, Sanofi, Servier
and Takeda. This article is a short opinion piece and has not been submitted to
external peer reviewers but was reviewed by a member of the Editorial Board
Stefano Del Prato, Department of Clinical and
Experimental Medicine University of Pisa, Via Roma 67,. I-56100 Pisa, Italy.
The publication of this article was supported by Novartis Pharma AG.
This article is published under the Creative Commons Attribution
Noncommercial License, which permits any non-commercial use, distribution,
adaptation and reproduction provided the original author(s) and source are given
Share this Article
Related Content In Diabetes
Bexagliflozin as an Adjunct Therapy to Diet and Exercise to Improve Glycaemic Control in Adults with Type 2 Diabetes
touchREVIEWS in Endocrinology. 2024;20(1):Online ahead of journal publication
Type 2 diabetes (T2D) is one of the most common chronic noncommunicable diseases, its incidence is exponentially increasing and is one of the leading causes of morbidity and mortality worldwide.1 As of 2021, T2D ranked among the top causes of premature death and was responsible for more than 6.5 million deaths.2 Currently, approximately 537 million people (over […]
Foreword: touchREVIEWS in Endocrinology 19.2
Welcome to the latest edition of touchREVIEWS in Endocrinology. In this issue we feature a range of articles to keep you up to date with the latest discussions and developments in the field of medical endocrinology. We start with an expert interview from the Founder and CEO of the Global Liver Institute, Donna Cryer, who […]
Teplizumab in Type 1 Diabetes Mellitus: An Updated Review
touchREVIEWS in Endocrinology. 2023;19(2):22-30
Type 1 diabetes mellitus (T1DM) is an autoimmune disease secondary to the destruction of the insulin-producing β cells of the islets of the pancreas. Environmental factors presumably trigger the disease in genetically susceptible individuals, leading to a lifetime dependency on exogenous insulin.1 The risk of T1DM in the general population is 0.4% but increases to 1–9% […]